(NASDAQ: MDGL) Madrigal Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.51%.
Madrigal Pharmaceuticals's revenue in 2023 is $0.On average, 7 Wall Street analysts forecast MDGL's revenue for 2024 to be $3,795,958,032, with the lowest MDGL revenue forecast at $1,708,923,438, and the highest MDGL revenue forecast at $8,344,229,332. On average, 6 Wall Street analysts forecast MDGL's revenue for 2025 to be $12,134,185,599, with the lowest MDGL revenue forecast at $6,329,689,734, and the highest MDGL revenue forecast at $22,439,294,017.
In 2026, MDGL is forecast to generate $24,762,608,598 in revenue, with the lowest revenue forecast at $18,367,965,559 and the highest revenue forecast at $35,642,188,530.